Meiragtx (MGTX) Stock
Clinical stage gene therapy company for inherited eye diseases. Here's the price, business snapshot, and what's worth knowing about Meiragtx in October 2026.
MeiraGTx Holdings plc (MGTX) is a clinical‑stage gene therapy company developing treatments for inherited retinal diseases, neurological and metabolic disorders. The group has a diversified pipeline of programmes at various stages, partnerships for research and manufacturing, and a focus on adeno‑associated virus (AAV) delivery platforms. With a market capitalisation of about $744.94M, investors typically monitor trial readouts, regulatory milestones and partnering activity as primary value drivers. As with many biotech companies, MeiraGTx does not have a long track record of commercial revenues and can be dependent on external funding and successful clinical outcomes. Catalysts can produce significant share‑price moves, but trial setbacks, regulatory decisions or capital needs can have the opposite effect. This summary is for educational purposes only and is not personal financial advice; suitability depends on individual circumstances and risk tolerance.
Meiragtx (MGTX) Stock Forecast
Analyst price target, next 12 months
$22.50
+108.5% vs today's $10.79
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Meiragtx have a consensus 12-month target of $22.50, above the current price of $10.79.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 5 Oct 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying MEIRAGTX Holdings stock with a target price of $22.5, indicating good potential for growth.
Financial Health
MEIRAGTX Holdings is performing well, showing strong revenue and profit margins, with healthy cash flow.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Pipeline Momentum
Multiple clinical readouts and regulatory milestones can create share‑price catalysts, though individual trials carry binary outcomes and high uncertainty.
Manufacturing & Partnerships
Capabilities and alliances for vector production are strategic strengths, but scaling and quality control can be costly and technically demanding.
Volatility & Funding
Biotech equities are often volatile and may require further capital to advance programmes; investors should be prepared for swings and dilution risk.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
